ReviewInternational journal of molecular sciences2025
Aldosterone: From Essential Tubular Regulator to Pathological Driver-Physiology, Disease, and Therapeutic Advances.
Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Mechanisms for Mineralocorticoid-Driven Age-Related Hypertension: Potential Therapeutic Role of Mineralocorticoid Receptor Antagonists and Aldosterone Synthase Inhibitors.Circulation research · 2026Review
- Myeloid cell renin-angiotensin-aldosterone system in hypertension and inflammation.Current opinion in physiology · 2026Article
- Familial Hyperaldosteronism Type IV (FH-IV)-Clinical Phenotypes, Genetics and Management ofJournal of clinical medicine · 2026Review
- Hemodynamic effects of finerenone on blood pressure and heart rate in hospitalized patients with type 2 diabetes: a real-world study.Frontiers in endocrinology · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aldosterone is a key regulator of sodium reabsorption, potassium secretion, and acid-base balance along the aldosterone-sensitive distal nephron (ASDN), where it exerts coordinated, segment-specific control over tubular transport. Although essential for volume conservation in terrestrial environments, aldosterone signaling has become maladaptive in modern sodium-rich contexts, contributing to systemic inflammation, fibrosis, and progression of cardiovascular and kidney disease. This review examines the regulation of aldosterone biosynthesis, the molecular diversity of mineralocorticoid receptor (MR) signaling, and the cellular mechanisms by which aldosterone shapes ion transport in the ASDN. A detailed classification of aldosterone-related disorders is presented, including hyperaldosteronism, pseudo-hyperaldosteronism, aldosterone resistance, and hypoaldosteronism. The therapeutic section focuses on MR overactivation in chronic kidney disease, critically appraising the clinical use of steroidal and non-steroidal MR antagonists. In addition, emerging strategies targeting aldosterone synthesis and downstream inflammatory pathways are discussed as potential approaches to address residual cardiorenal risk and the aldosterone breakthrough phenomenon. Together, these insights support a mechanistic reappraisal of aldosterone as both a physiological modulator and a pathologic driver, with implications for biomarker-guided, targeted therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.